Overall, our comprehensive study of the molecular and clinicopathological features of CD96 through 1,001 samples will provide a better understanding of CD96 in glioma and pave the way for developing CD96-targeted cancer immunotherapies. The gene discussed is CD96; the disease is central nervous system cancer.